<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805180</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-5010</org_study_id>
    <nct_id>NCT01805180</nct_id>
  </id_info>
  <brief_title>Evaluation of the Spectra Optia PMN Cell Collection Procedure</brief_title>
  <acronym>PMNC</acronym>
  <official_title>A Controlled Evaluation of the Spectra Optia® Apheresis System's Granulocyte / Polymorphonuclear (PMN) Cell Collection Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the procedures for the collection PMN cells on Terumo
      BCT's Spectra Optia® and COBE® Spectra Apheresis Systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the procedures for the collection of granulocyte/
      polymorphonuclear (PMN) cells on Terumo BCT's Spectra Optia® and COBE® Spectra Apheresis
      Systems and to establish the non-inferiority of the Spectra Optia Apheresis System with
      respect to the primary study endpoint, granulocyte/PMN cell collection efficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Granulocyte/PMN Cell Collection Efficiency</measure>
    <time_frame>within 1 hour prior and within 5 minutes after each collection procedure</time_frame>
    <description>The primary endpoint is the granulocyte/PMN cell collection efficiency (CE) associated with the Granulocyte (PMN) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the PMN collection procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>within 1 hour prior and within 5 minutes after each collection procedure</time_frame>
    <description>Comparison of collection efficiencies associated with the Granulocyte Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for white blood cells and platelets. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Blood Product - PMN Cell Yield</measure>
    <time_frame>within 5 minutes after each collection procedure</time_frame>
    <description>Characterization of the collected blood product, specifically total PMN cell yield. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Blood Product - PMN Cell Yield Per Liter of Blood Processed</measure>
    <time_frame>within 5 minutes after each collection procedure</time_frame>
    <description>Characterization of the collected blood product, specifically PMN cell yield per liter blood processed. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product and blood processed measured by the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the Blood Product - PMN Cell Viability</measure>
    <time_frame>within 5 minutes after collection procedure</time_frame>
    <description>Characterization of the collected blood product, specifically PMN cell viability measured by an assay preformed on the collected blood product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the Blood Product - RBC Contamination</measure>
    <time_frame>within 5 minutes after collection procedure</time_frame>
    <description>Characterization of the collected blood product, specifically red blood cell (RBC) contamination as measured by hematocrit in the collected PMN product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the Blood Product - Volume</measure>
    <time_frame>within 5 minutes after collection procedure</time_frame>
    <description>Characterization of the collected blood product, specifically product volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability/Assessment of System Operation - Time</measure>
    <time_frame>Result captured immediately upon completion of procedure</time_frame>
    <description>Procedure time for collections on the Spectra Optia vs. the COBE Spectra.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability/Assessment of System Operation - Adjustments</measure>
    <time_frame>Adjustments known immediately upon completion of the procedure</time_frame>
    <description>Number of operator adjustments aimed at establishing and maintaining the plasma/ cellular interface: namely, on Spectra Optia, the adjustment of collection preference and, on COBE Spectra, the adjustment of the plasma pump flow rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability/Assessment of System Operation - Device Malfunctions</measure>
    <time_frame>Result know immediately upon successful completion of procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>48-hours after last procedure</time_frame>
    <description>Serious adverse events (SAEs) and unanticipated (serious) adverse device/procedure- related events (UADEs), adverse events (AEs).
any clinically significant changes to Complete Blood Count with differential white cell count (CBCD) and any significant changes to vital signs (temperature, heart rate, blood pressure) were captured as AEs. Also provided in full report to FDA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Granulocyte/ Polymorphonuclear Cells</condition>
  <arm_group>
    <arm_group_label>Arm 1: Spectra Optia followed by COBE Spectra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: COBE Spectra followed by Spectra Optia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)</intervention_name>
    <description>In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.</description>
    <arm_group_label>Arm 1: Spectra Optia followed by COBE Spectra</arm_group_label>
    <arm_group_label>Arm 2: COBE Spectra followed by Spectra Optia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)</intervention_name>
    <description>In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.</description>
    <arm_group_label>Arm 1: Spectra Optia followed by COBE Spectra</arm_group_label>
    <arm_group_label>Arm 2: COBE Spectra followed by Spectra Optia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acceptable health status and vital signs per the AABB blood donation guidelines to
             permit blood donation, including:

               1. Blood pressure ≥ 90/50 and ≤ 200/120 mmHg,

               2. Pulse &gt; 40 and &lt; 100 beats/min, and

               3. Temperature &lt; 99.5ºFahrenheit (F).

          -  Able to read, understand, and sign an English informed consent form.

          -  Age ≥ 18 years.

          -  Weight ≥ 50kg and &lt; 227kg.

          -  Male or non-pregnant, non-nursing female (a negative serum pregnancy test at screening
             and a negative urine pregnancy test prior to each mobilization).

          -  Acceptable screening laboratory test results prior to the first PMN cell mobilization,
             including:

               1. WBC count in the range: 3,500-10,800/uL,

               2. Hematocrit in the range: 38-65%,

               3. Platelet count in the range: 150,000-400,000/uL,

               4. Coagulation tests: PT not greater than 1.1 times the upper limit of the local
                  laboratory reference range; PTT not greater than 1.2 times the upper limit of the
                  local laboratory reference range,

               5. Serum electrolyte concentrations: potassium in the range 3.6-5.1 mmol/L; calcium
                  in the range 8.5-10.3 mg/dL,

               6. Serum creatinine not greater than 1.5mg/dL, and

               7. ALT not greater than 1.5 times the upper limit of the local laboratory reference
                  range. *** Up to two (2) of the above screening laboratory test results may fall
                  outside of these ranges, if in the judgment of the principal investigator or
                  designee, they do not constitute a significant risk to the subject. Any excused
                  deviations from the above will be listed and summarized with the final report.***

          -  Adequate dual peripheral venous access to allow collection of granulocytes (PMN cells)
             and return of remaining cells, platelets and plasma.

          -  If male, willing to use a condom during sexual relations with a female partner of
             child bearing potential until 48 hours following each G-CSF injection.

          -  If female, willing to use a medically-acceptable contraceptive until 48 hours
             following each G-CSF injection.

        Exclusion Criteria:

          -  Positive screening for any of the following: HIV, HBV (except isolated HB core Ab
             reactivity), HCV, HTLV, Syphilis or West Nile Virus.

          -  Currently pregnant or breast-feeding.

          -  Collection or loss of specific volumes of whole blood or blood components during
             specified timeframes:

               1. more than 550mL of whole blood within the prior 56 days, or

               2. more than 3L of whole blood or 1.5L of red blood cells within the prior 12
                  months, or

               3. more than 12L of plasma within the prior 12 months, or

               4. a leukapheresis within the prior six weeks, or

               5. a plateletpheresis within the prior 48 hours or two within the prior 7 days or
                  twenty-four within the last 12 months, or

               6. a plasmapheresis within the prior 48 hours or two within the prior 7 days.

          -  History of congestive heart failure.

          -  History of uncontrolled hypertension (SBP/DBP &gt;200/120 mmHg).

          -  History or suspicion of active, peptic ulcer disease.

          -  History of diabetes mellitus.

          -  History of hematologic malignancy or chronic hematologic disorder.

          -  Family history (parents, siblings, children) of hematologic malignancy.

          -  History of deep vein thrombosis or venous thromboembolism, or bleeding disorder.

          -  History of sickle cell disease or a positive SickleDex screen.

          -  History of iritis or episcleritis.

          -  History of autoimmune condition or disorder, unless approved by principal
             investigator.

          -  Presence of psychological traits, or physiological or medical conditions that, in the
             opinion of the investigator, would make the subject unlikely to tolerate the
             procedures or complete the study.

          -  History of use/anticipated need for lithium.

          -  Received a G-CSF injection in the prior 4 months.

          -  Known hypersensitivity to ethylene oxide.

          -  Known hypersensitivity to G-CSF or hypersensitivity to any E. coli-derived products.

          -  Known hypersensitivity to HES or corn.

          -  Concurrent participation in another clinical trial or participation in a clinical
             trial within the past 30 days.

          -  Subject is being treated with calcium channel blockers and/or antiepileptic
             medications. Note: This applies only to Subjects at Bonfils Blood Center whose
             collected product will undergo neutrophil function testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Goodrich, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Terumo BCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bonfils Blood Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Centers of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>February 27, 2015</last_update_submitted>
  <last_update_submitted_qc>February 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the specialized donor population of blood centers from February 2013 - July 2013.</recruitment_details>
      <pre_assignment_details>A screening period was used to evaluate and confirm eligibility criteria prior to enrollment &amp; randomization to treatment assignment (Arm 1 or Arm 2). Fifty subjects consented to the pivotal study. Eight pivotal subjects consented but screen failed prior to treatment assignment. Forty-two received treatment assignment below.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lead-in Donor</title>
          <description>Subjects screened and enrolled for the purpose of training on the investigational procedure only. Included in safety analysis only.</description>
        </group>
        <group group_id="P2">
          <title>Arm 1 - Spectra Optia Followed by COBE Spectra PMN</title>
          <description>Healthy donors who were consented to participate in the pivotal trial and were randomized to receive the PMN collection procedure on the Spectra Optia first, followed by the COBE Spectra.</description>
        </group>
        <group group_id="P3">
          <title>Arm 2 - COBE Spectra Followed by Spectra Optia PMN</title>
          <description>Healthy donors who were consented to participate in the pivotal trial and were randomized to receive the PMN collection procedure on the COBE Spectra first, followed by the Spectra Optia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Lead-in Donor Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0">pivotal trial subjects were not screened or enrolled in this period.</participants>
                <participants group_id="P3" count="0">pivotal trial subjects were not screened or enrolled in this period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pivotal Randomization Through Study Exit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">lead-in donors were not randomized and did not participate in this period.</participants>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects in the Full Set Analysis (n=32) were randomized to either Arm 1 or Arm 2 and completed both procedures as assigned. Subjects who did not complete the collection (withdrawn n=10) did not have data and could not be included in the full set analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="10.99"/>
                    <measurement group_id="B2" value="38.3" spread="13.69"/>
                    <measurement group_id="B3" value="36.3" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Granulocyte/PMN Cell Collection Efficiency</title>
        <description>The primary endpoint is the granulocyte/PMN cell collection efficiency (CE) associated with the Granulocyte (PMN) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the PMN collection procedure.</description>
        <time_frame>within 1 hour prior and within 5 minutes after each collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Granulocyte/PMN Cell Collection Efficiency</title>
          <description>The primary endpoint is the granulocyte/PMN cell collection efficiency (CE) associated with the Granulocyte (PMN) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the PMN collection procedure.</description>
          <units>percent cells processed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="6.46"/>
                    <measurement group_id="O2" value="52.4" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" spread="6.14"/>
                    <measurement group_id="O2" value="44.7" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance</title>
        <description>Comparison of collection efficiencies associated with the Granulocyte Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for white blood cells and platelets. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure.</description>
        <time_frame>within 1 hour prior and within 5 minutes after each collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance</title>
          <description>Comparison of collection efficiencies associated with the Granulocyte Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for white blood cells and platelets. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure.</description>
          <units>percent of cells processed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia WBC CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="6.15"/>
                    <measurement group_id="O2" value="55.4" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra WBC CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="0.06"/>
                    <measurement group_id="O2" value="46.9" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spectra Optia PLT CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="1.59"/>
                    <measurement group_id="O2" value="10.4" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra PLT CE%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="3.09"/>
                    <measurement group_id="O2" value="9.7" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Blood Product - PMN Cell Yield</title>
        <description>Characterization of the collected blood product, specifically total PMN cell yield. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product.</description>
        <time_frame>within 5 minutes after each collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Blood Product - PMN Cell Yield</title>
          <description>Characterization of the collected blood product, specifically total PMN cell yield. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product.</description>
          <units>cells *10^10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia PMN Cell Yield</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.30"/>
                    <measurement group_id="O2" value="1.4" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra PMN Cell Yield</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.28"/>
                    <measurement group_id="O2" value="1.2" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Blood Product - PMN Cell Yield Per Liter of Blood Processed</title>
        <description>Characterization of the collected blood product, specifically PMN cell yield per liter blood processed. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product and blood processed measured by the device.</description>
        <time_frame>within 5 minutes after each collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Blood Product - PMN Cell Yield Per Liter of Blood Processed</title>
          <description>Characterization of the collected blood product, specifically PMN cell yield per liter blood processed. This is a measurement of device performance measured by calculating cell counts in samples from the collected blood product and blood processed measured by the device.</description>
          <units>cells *10^10 per L of blood processed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia PMN Cell Yield per L of Blood Proces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.30"/>
                    <measurement group_id="O2" value="1.4" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra PMN Cell Yield per L of Blood Proc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.28"/>
                    <measurement group_id="O2" value="1.2" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of the Blood Product - PMN Cell Viability</title>
        <description>Characterization of the collected blood product, specifically PMN cell viability measured by an assay preformed on the collected blood product.</description>
        <time_frame>within 5 minutes after collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of the Blood Product - PMN Cell Viability</title>
          <description>Characterization of the collected blood product, specifically PMN cell viability measured by an assay preformed on the collected blood product.</description>
          <units>percent of viable cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia PMN viability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" spread="0.22"/>
                    <measurement group_id="O2" value="99.6" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra PMN viability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" spread="0.34"/>
                    <measurement group_id="O2" value="99.2" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of the Blood Product - RBC Contamination</title>
        <description>Characterization of the collected blood product, specifically red blood cell (RBC) contamination as measured by hematocrit in the collected PMN product.</description>
        <time_frame>within 5 minutes after collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectra Optia vs COBE Spectra</title>
            <description>All 32 subjects received both the Spectra Optia and the COBE Spectra. RBC contamination results via hematocrit in collected product not reported by randomization treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of the Blood Product - RBC Contamination</title>
          <description>Characterization of the collected blood product, specifically red blood cell (RBC) contamination as measured by hematocrit in the collected PMN product.</description>
          <units>RBC percent of product volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia Product HCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra Product HCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of the Blood Product - Volume</title>
        <description>Characterization of the collected blood product, specifically product volume.</description>
        <time_frame>within 5 minutes after collection procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of the Blood Product - Volume</title>
          <description>Characterization of the collected blood product, specifically product volume.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia Product Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472.6" spread="1.77"/>
                    <measurement group_id="O2" value="471.9" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra Product Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.7" spread="55.72"/>
                    <measurement group_id="O2" value="298.5" spread="53.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usability/Assessment of System Operation - Time</title>
        <description>Procedure time for collections on the Spectra Optia vs. the COBE Spectra.</description>
        <time_frame>Result captured immediately upon completion of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Usability/Assessment of System Operation - Time</title>
          <description>Procedure time for collections on the Spectra Optia vs. the COBE Spectra.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia Procedure Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.8" spread="20.78"/>
                    <measurement group_id="O2" value="120.3" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra Procedure Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.6" spread="18.65"/>
                    <measurement group_id="O2" value="112.3" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usability/Assessment of System Operation - Adjustments</title>
        <description>Number of operator adjustments aimed at establishing and maintaining the plasma/ cellular interface: namely, on Spectra Optia, the adjustment of collection preference and, on COBE Spectra, the adjustment of the plasma pump flow rate.</description>
        <time_frame>Adjustments known immediately upon completion of the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Spectra Optia Followed by COBE Spectra</title>
            <description>In Arm 1 the first PMN cell collection was performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System for each subject.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COBE Spectra Followed by Spectra Optia</title>
            <description>In Arm 2 the first PMN cell collection was performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System for each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Usability/Assessment of System Operation - Adjustments</title>
          <description>Number of operator adjustments aimed at establishing and maintaining the plasma/ cellular interface: namely, on Spectra Optia, the adjustment of collection preference and, on COBE Spectra, the adjustment of the plasma pump flow rate.</description>
          <units>number of adjustments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia adjustments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.12"/>
                    <measurement group_id="O2" value="5.8" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra adjustments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="3.67"/>
                    <measurement group_id="O2" value="10.7" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usability/Assessment of System Operation - Device Malfunctions</title>
        <time_frame>Result know immediately upon successful completion of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectra Optia vs COBE Spectra</title>
            <description>All 32 subjects received both the Spectra Optia and the COBE Spectra. Device deficiency was not reported by randomization treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Usability/Assessment of System Operation - Device Malfunctions</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia device deficiencies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra device deficiencies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Serious adverse events (SAEs) and unanticipated (serious) adverse device/procedure- related events (UADEs), adverse events (AEs).
any clinically significant changes to Complete Blood Count with differential white cell count (CBCD) and any significant changes to vital signs (temperature, heart rate, blood pressure) were captured as AEs. Also provided in full report to FDA.</description>
        <time_frame>48-hours after last procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectra Optia vs COBE Spectra</title>
            <description>All 32 subjects received both the Spectra Optia and the COBE Spectra. RBC contamination results via hematocrit in collected product not reported by randomization treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Serious adverse events (SAEs) and unanticipated (serious) adverse device/procedure- related events (UADEs), adverse events (AEs).
any clinically significant changes to Complete Blood Count with differential white cell count (CBCD) and any significant changes to vital signs (temperature, heart rate, blood pressure) were captured as AEs. Also provided in full report to FDA.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spectra Optia SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spectra Optia UADEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COBE Spectra UADEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects with &gt;=1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the point of randomization until 48-hours after the last study procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Spectra Optia</title>
          <description>A total of n=48 subjects were either randomized to receive a procedure (n=42) or were assigned the Spectra Optia as a lead-in subject (lead-in n=6). Lead-in donors were not randomized and received the Spectra Optia only for training purposes and are included for Spectra Optia safety only. Randomized subjects are included in safety regardless if they withdrew or did not complete a procedure. Spectra Optia events are AEs during the study period when the subject received the Spectra Optia.</description>
        </group>
        <group group_id="E2">
          <title>COBE Spectra</title>
          <description>A total of n=42 subjects were randomized to receive a procedure. Randomized subjects are included in safety regardless if they withdrew or did not complete a procedure. Lead-in subjects are never exposed to COBE Spectra per protocol and not included. COBE Spectra events are AEs during the study period when the subject received the COBE Spectra.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <description>expected due to mobilization medication</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <description>expected due to mobilization medication</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>sore shoulder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>expected due to mobilization medication</description>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <description>expected due to mobilization medication</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>haematoma</sub_title>
                <description>expected related to venipuncture</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Full Analysis Set included 32 subjects who completed both procedures of the cross-over study design presented here. Two subjects did not meet pre-defined criteria for evaluable and 30 subjects were included in the Evaluable Analysis Population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raymond P. Goodrich, PhD / VP, Scientific and Clinical Affairs; Chief Science Officer-BBT</name_or_title>
      <organization>Terumo BCT</organization>
      <phone>303.205.2680</phone>
      <email>Ray.Goodrich@terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

